Private equity deals for universities

Plus: Cogent says its rare disease drug will hit a 'home run.' Blueprint executives think otherwise

June 20, 2025 Check out STAT+

Sponsored By

David L Ryan/Globe Staff STAT+ | More universities open to private equity deals, and emerging companies turn to new targets During Day 3 of BIO, we're covering universities' willingness for private equity deals and a new era for obesity drug development. By Allison DeAngelis and Elizabeth Cooney STAT+ | Cogent Biosciences-Blueprint Medicines tiff turns spicy on eve of immune drug study readout In this week's edition of "Adam's Biotech Scorecard," Adam looks at drugs for indolent systemic mastocytosis, a common form of an immune system disorder. By Adam Feuerstein Opinion: The MAHA children's health report mis-cited our research. That's sloppy — and worrying Two of our papers were cited in the MAHA report as evidence about the dangers of advertising to children — except they weren't. By Steven Woloshin and Richard L. Kravitz STAT Why MAHA wants whole milk back on the table In the nutrition world, the question of how whole milk compares with lower-fat options is the subject of debate. In MAHA world, it's time to embrace change. By Sarah Todd

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser